Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 608-711-3 | CAS number: 32167-31-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study meets generally accepted scientific standards with restrictions due to the limited documentation.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 972
- Report date:
- 1972
Materials and methods
- Principles of method if other than guideline:
- BASF internal standardized test: Aqueous preparations of the test substance were injected into the peritoneal cavity of the mice. Group-wise documentation of clinical signs was performed over the 7-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose. The clinical signs and findings were reported in summary form.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Oligomerisation products of but-2-yne-1,4-diol and ethylene oxide
- EC Number:
- 608-711-3
- Cas Number:
- 32167-31-0
- Molecular formula:
- C4 H6 O2 (C2 H4 O) n, where 1 < n < 4.5
- IUPAC Name:
- Oligomerisation products of but-2-yne-1,4-diol and ethylene oxide
- Details on test material:
- - Name of test material (as cited in study report): Golpanol BEO = Golpanol SC 9189
- Physical state: liquid
- Analytical purity: no data
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Kisslegg, Germany
- Mean body weight at study initiation: males 28.9 g, females 23.2 g
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- water
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 16% (w/v)
- Form of application: aqueous suspension
MAXIMUM DOSE VOLUME APPLIED: 15.6 mL/kg bw
- Doses:
- 729.6, 912.6, 1136, 1422.75, 1824 and 2280 mg/kg bw (conversion of original values (640, 800, 1000, 1250, 1600, 2000 mL/kg bw) using the density of 1.14 g/cm³)
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days
- Frequency of observations and weighing: Body weight was determined before the beginning of the study for dose calculation.
Observation of clinical signs was several times on the day of administration and once daily afterwards with the exception of weekends and on holidays.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 1 026 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: original value 900 µL/kg bw (conversion using the density of 1.14 g/cm³)
- Mortality:
- 729.6 mg/kg bw: no deaths occured (males and females).
912 mg/kg bw: 3/10 animals (males: 3/5 animals died within 24 hours after treatment; females: 0/5 animals died).
1136.35 mg/kg bw: 6/10 animals (males: 4/5 animals died within 24 hours, 5/5 animals were dead at the end of the observation period of 7 days after treatment; females: 1/5 animals died within 24 hours after tretament).
1422.75 mg/kg bw: 7/10 animals (males: 5/5 animals died within 24 hours after treatment; females: 1/5 animals died within 24 hours after tretament and 1/5 within 48 hours, in total 2/5 females were dead at the end of the observation period).
1824 mg/kg bw: males: 8/10 animals (4/5 animals died within 24 hours after treatment, 5/5 animals were dead at the end of the observation period of 7 days; females: 3/5 animals died within 24 hours after treatment).
2280 mg/kg bw: males: 9/10 animals (4/5 animals died within 24 hours after treatment, 5/5 animals were dead at the end of the observation period of 7 days; females: 5/5 animals died within 24 hours after treatment). - Clinical signs:
- After treatment accelerated breathing, stagger, scampered gait, shrunken flanks and cloudy eyes were observed. After half a day the animals of the 2280 mg/kg bw and 1824 mg/kg bw dose level showed partly abdominal position. On the following days crouching position, intermittent and accelerated breathing and partly closed eyes were noted. No abnormality was detected in surviving animals between the 4th and 7th day after treatment.
- Gross pathology:
- sacrificed animals: 1136.35 mg/kg bw: 2/4 females: liver: 2 pinhead sized necrosis
perished animals: 2280 mg/kg bw: 1/3 males: liver: loam-yellow-grey with nutmeg-like pattern indicate congestive hepatopathy.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live2